Skip to content
10-Q

Quarterly Report

Theravance Biopharma, Inc. TBPH

0001104659-26-056760

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · Apr 30, 2026 51.55M sh
Shares Diluted Q1 2026 · Mar 31, 2026 51.28M sh
Shares Diluted Q1 2026 · Mar 31, 2025 49.71M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 $73.28M
Operating Cash Flow Q1 2026 · Mar 31, 2025 $43.04M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $288.1M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $167.81M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $110.61M
Stockholders Equity Q1 2026 · Mar 31, 2026 $290.59M
Stockholders Equity Q1 2026 · Dec 31, 2025 $296.72M
Current Liabilities Q1 2026 · Mar 31, 2026 $31.78M
Current Liabilities Q1 2026 · Dec 31, 2025 $38.3M
Current Assets Q1 2026 · Mar 31, 2026 $417.63M
Current Assets Q1 2026 · Dec 31, 2025 $418.46M
Total Assets Q1 2026 · Mar 31, 2026 $472.31M
Total Assets Q1 2026 · Dec 31, 2025 $485.57M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.10
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.27
Eps Basic Q1 2026 · Mar 31, 2026 −$0.10
Eps Basic Q1 2026 · Mar 31, 2025 −$0.27
Sga Expense Q1 2026 · Mar 31, 2026 $17.72M
Sga Expense Q1 2026 · Mar 31, 2025 $18.37M
Rd Expense Q1 2026 · Mar 31, 2026 $5.83M
Rd Expense Q1 2026 · Mar 31, 2025 $11.45M
Net Income Q1 2026 · Mar 31, 2026 −$4.93M
Net Income Q1 2026 · Mar 31, 2025 −$13.58M
Operating Income Q1 2026 · Mar 31, 2026 −$9.48M
Operating Income Q1 2026 · Mar 31, 2025 −$14.43M
Revenue Q1 2026 · Mar 31, 2026 $17.7M
Revenue Q1 2026 · Mar 31, 2025 $15.39M